Shots:
- AstraZeneca has reported P-III (LOGOS & KALOS) trial results evaluating Breztri Aerosphere (BGF; 320/28.8/9.6μg or 320/14.4/9.6μg) vs PT009 (ICS/LABA via Aerosphere) & Symbicort pressurized metered-dose inhaler (pMDI) in pts (n=~4400) with uncontrolled asthma
- Trial met its 1EP, with BGF 320/28.8/9.6μg showing significant improvement in forced expiratory volume in 1 second (FEV1) AUC 0 to 3hrs. at Wk. 24 & in trough FEV1 over Wks. 12–24 & across 24wks.; data to be shared with global health authorities & presented at future meetings
- Breztri Aerosphere is a single-inhaler triple therapy combination of formoterol (LABA), glycopyrronium (LAMA), & budesonide (ICS), delivered via Aerosphere pMDI
Ref: AstraZeneca | Image: AstraZeneca
Related News:- Daiichi Sankyo & AstraZeneca Report Topline P-III (DESTINY-Breast09) Trial Data of Enhertu for HER2+ Metastatic Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
